Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 256

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 256
---
526  
     691,770 
  
    General and Administrative Expenses 
     5,024,985  
     4,241,836 
  
    Total Operating Expenses 
     10,011,511  
     4,933,606 

    Loss from Operations 
     (9,714,931) 
     (5,154,583)

    Interest Expense 
     (7,912) 
     (2,286,637)
  
    Derivative Expense 
     -  
     (399,725)
  
    Change in Fair Value of Derivative Liabilities 
     1,665,966  
     (37,278)
  
    Loss on Debt Extinguishment 
     -  
     (1,231,480)
  
    Change in Fair Value of Promissory Note 
     -  
     5,379,269 
  
    Other Income (Expense), net 
     101,464  
     (83,116)
  
    Total Interest and Other Income (Expense), net 
     1,759,518  
     1,341,033 
  
    Loss from Operations before Provision for Income Taxes 
     (7,955,413) 
     (3,813,550)
  
    Provision for Income Taxes (Note 9) 
     250  
     250 
  
    Net Loss including Noncontrolling Interest 
     (7,955,663) 
     (3,813,800)
  
    Net Loss  – Noncontrolling Interest 
     (8,556) 
     (48,098)
  
    Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
    $(7,947,107) 
    $(3,765,702)

48

The following table sets forth our results of
operations as a percentage of revenue:

    For the Year Ended
    December 31, 
  
    Consolidated Statements of Operations Data: 
    2024  
    2023 
  
    Product Revenues – net of Discounts and Rebates 
     100.00% 
     100.00%
  
    Cost of Revenues 
     63.33  
     187.15 
  
    Gross Profit (Loss) 
     36.67  
     (87.15)
  
    Research Revenues